Lexicon Pharmaceuticals (STU:LX31) OCF Margin %: -69.80% (As of Mar. 2026)

What is Lexicon Pharmaceuticals OCF Margin %?

Lexicon Pharmaceuticals STU:LX31 53 OCF Margin % is -69.80% as of Mar. 2026. GuruFocus rates STU:LX31 with a GF Score™ of 53/100 and a GF Value™ of €15.33. The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Lexicon Pharmaceuticals ranks better than 51.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Lexicon Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2026 was €-12.74 Mil. Lexicon Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €18.25 Mil. Therefore, Lexicon Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2026 was -69.80%.

As of today, Lexicon Pharmaceuticals's current OCF Yield % is -3.93%.

The historical rank and industry rank for Lexicon Pharmaceuticals's OCF Margin % or its related term are showing as below:

STU:LX31' s OCF Margin % Range Over the Past 10 Years
Min: -63921.58 Med: -405.16 Max: 35.34
Current: -55

During the past 13 years, the highest OCF Margin % of Lexicon Pharmaceuticals was 35.34%. The lowest was -63921.58%. And the median was -405.16%.

STU:LX31's OCF Margin % is ranked better than
51.56% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs STU:LX31: -55.00

Lexicon Pharmaceuticals OCF Margin % Related Terms

Lexicon Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for Lexicon Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexicon Pharmaceuticals OCF Margin % Chart

Lexicon Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-29,170.45

-64,026.72

-13,447.46

-575.21

-136.24

Lexicon Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-3,470.01	58.87	-168.05	-313.73	-69.80

STU:LX31 vs SPTX, DRTS, MGTX: OCF Margin % Comparison

For the Biotechnology subindustry, Lexicon Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexicon Pharmaceuticals OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's OCF Margin % falls into.

Save Embed

53GF Score

Lexicon Pharmaceuticals Inc STU:LX31

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lexicon Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Lexicon Pharmaceuticals's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-57.945	/	42.532
	=	-136.24 %

Lexicon Pharmaceuticals's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-12.741	/	18.253
	=	-69.80 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -69.80% mean?

Lexicon Pharmaceuticals (STU:LX31) has a OCF Margin % of -69.80% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lexicon Pharmaceuticals and its competitors. According to the industry distribution chart, Lexicon Pharmaceuticals ranks #465 out of 960 companies in the Biotechnology industry, placing it in the top 48.4%.

Is Lexicon Pharmaceuticals' OCF Margin % too high?

Lexicon Pharmaceuticals' current OCF Margin % is -69.80%. Based on the distribution chart, Lexicon Pharmaceuticals ranks #465 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lexicon Pharmaceuticals has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.

How does Lexicon Pharmaceuticals' OCF Margin % compare to SPTX and DRTS?

According to the Biotechnology industry distribution chart, Lexicon Pharmaceuticals ranks #465 out of 960 companies for OCF Margin %. This puts Lexicon Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lexicon Pharmaceuticals and its competitors. Lexicon Pharmaceuticals's current OCF Margin % is -69.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lexicon Pharmaceuticals stock overvalued right now?

Lexicon Pharmaceuticals (STU:LX31) has a current OCF Margin % of -69.80%. The stock's GF Value™ is €15.33, compared to a current price of €4.10 — trading 73.3% below its estimated fair value. The current OCF Margin % is -69.80%. Lexicon Pharmaceuticals' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Lexicon Pharmaceuticals (STU:LX31), the current OCF Margin % is -69.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexicon Pharmaceuticals (STU:LX31) Overvalued in 2026?

Based on GuruFocus' analysis, Lexicon Pharmaceuticals stock appears to be undervalued. The current stock price of €4.10 is trading 73.3% below its estimated GF Value™ of €15.33.

Key valuation signals for STU:LX31:

OCF Margin %: -69.80%
GF Value™: €15.33 vs. price of €4.10 (73.3% below fair value)
GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:LX31 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexicon Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies SPTX DRTS MGTX CGEM SANA KURA ABUS SPRY JBIO JANX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges LXRX:USA

Address 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381

Website https://www.lexpharma.com

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

53GF Score

Get the complete analysis for STU:LX31

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.10

Price

€15.33

GF Value

View STU:LX31 Analysis

See OCF Margin % data for all stocks →